It builds on DeepMind’s work on protein folding
A new Alphabet company will use artificial intelligence methods for drug discovery, Google’s parent company announced Thursday. It’ll build off of the work done by DeepMind, another Alphabet subsidiary that has done groundbreaking work using AI to predict the structure of proteins.
The new company, called Isomorphic Laboratories, will leverage that success to build tools that can help identify new pharmaceuticals. DeepMind CEO Demis Hassabis will also serve as the CEO for Isomorphic, but the two companies will stay separate and collaborate occasionally, a spokesperson said.